Literature DB >> 18639501

Simplified method for determination of clarithromycin in human plasma using protein precipitation in a 96-well format and liquid chromatography-tandem mass spectrometry.

Jaekyu Shin1, Daniel F Pauly, Julie A Johnson, Reginald F Frye.   

Abstract

A simplified method to determine clarithromycin concentrations in human plasma using protein precipitation in a 96-well plate and liquid chromatography-tandem mass spectrometry was developed and validated. Plasma proteins were precipitated with acetonitrile and roxithromycin was used as the internal standard. After vortex mixing and centrifugation, the supernatants were directly injected onto a Phenomenex Luna Phenyl-Hexyl column (50 mm x 2.0 mm ID, 3 microm). The mobile phase consisted of water and methanol (30:70, v/v) containing 0.1% formic acid and 5mM ammonium acetate. The flow rate was 0.22 mL/min and the total run time (injection to injection) was less than 3 min. Detection of the analytes was achieved using positive ion electrospray tandem mass spectrometry in selected reaction monitoring (SRM) mode. The linear standard curve ranged from 100 to 5000 ng/mL and the precision and accuracy (inter- and intra-run) were within 7.9% and 4.9%, respectively. The method was successfully used to determine clarithromycin concentrations in human plasma samples obtained from healthy subjects who were given clarithromycin 500 mg for 3 days. The method is rapid, simple, precise and directly applicable to clarithromycin pharmacokinetic studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18639501      PMCID: PMC3832059          DOI: 10.1016/j.jchromb.2008.06.050

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  26 in total

1.  Sensitive liquid chromatography-tandem mass spectrometry method for the determination of clarithromycin in human plasma.

Authors:  G F van Rooyen; M J Smit; A D De Jager; H K L Hundt; K J Swart; A F Hundt
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2002-03-05       Impact factor: 3.205

Review 2.  Clinical inquiries. What regimens eradicate Helicobacter pylori?

Authors:  Wail Malaty; Sue Stigleman; Laura B Hansen
Journal:  J Fam Pract       Date:  2003-10       Impact factor: 0.493

3.  Determination of clarithromycin as a contaminant on surfaces by high-performance liquid chromatography using electrochemical detection.

Authors:  T D Rotsch; M Spanton; P Cugier; A C Plasz
Journal:  Pharm Res       Date:  1991-08       Impact factor: 4.200

4.  Simultaneous determination of clarithromycin and 14(R)-hydroxyclarithromycin in plasma and urine using high-performance liquid chromatography with electrochemical detection.

Authors:  S Y Chu; L T Sennello; R C Sonders
Journal:  J Chromatogr       Date:  1991-11-15

5.  Quantification of clarithromycin, its 14-hydroxy and decladinose metabolites in rat plasma, gastric juice and gastric tissue using high-performance liquid chromatography with electrochemical detection.

Authors:  J I D Wibawa; P N Shaw; D A Barrett
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2003-01-15       Impact factor: 3.205

6.  Liquid chromatographic determination of the macrolide antibiotics roxithromycin and clarithromycin in plasma by automated solid-phase extraction and electrochemical detection.

Authors:  M Hedenmo; B M Eriksson
Journal:  J Chromatogr A       Date:  1995-02-10       Impact factor: 4.759

7.  Ion-pair high-performance liquid chromatographic assay method for the assessment of clarithromycin stability in aqueous solution and in gastric juice.

Authors:  P O Erah; D A Barrett; P N Shaw
Journal:  J Chromatogr B Biomed Appl       Date:  1996-06-28

8.  A comparative clarithromycin bioavailability study: determination of clarithromycin and 14-(R)-hydroxyclarithromycin under fasting and fed conditions.

Authors:  P Benninger; A Cooper; R Moisan; P Patel; A Elvin; J J Thiessen
Journal:  Int J Clin Pharmacol Ther       Date:  2004-06       Impact factor: 1.366

Review 9.  Macrolides for the treatment of chronic sinusitis, asthma, and COPD.

Authors:  Mark H Gotfried
Journal:  Chest       Date:  2004-02       Impact factor: 9.410

10.  Metabolism and disposition of clarithromycin in man.

Authors:  J L Ferrero; B A Bopp; K C Marsh; S C Quigley; M J Johnson; D J Anderson; J E Lamm; K G Tolman; S W Sanders; J H Cavanaugh
Journal:  Drug Metab Dispos       Date:  1990 Jul-Aug       Impact factor: 3.922

View more
  5 in total

1.  Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin.

Authors:  Jaekyu Shin; Daniel F Pauly; Michael A Pacanowski; Taimour Langaee; Reginald F Frye; Julie A Johnson
Journal:  Pharmacotherapy       Date:  2011-10       Impact factor: 4.705

2.  Application of lactobionic acid and nonionic surfactants as solubilizing agents for parenteral formulation of clarithromycin.

Authors:  Parvin Zakeri-Milani; Niaz Mousavian-Fathi; Saeed Ghanbarzadeh; Mohammad-Hosein Zarrintan; Hadi Valizadeh
Journal:  Adv Pharm Bull       Date:  2012-02-15

3.  A Simple, Rapid and Reliable Method to Determine Imipramine and Desipramine in Mouse Serum Using Ultra-High-Performance Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry.

Authors:  Jing Zhao; Yujin Shin; Kwang-Hoon Chun; Hye-Ran Yoon; Jeongmi Lee
Journal:  J Chromatogr Sci       Date:  2015-12-19       Impact factor: 1.618

4.  Inhalable Clarithromycin Microparticles for Treatment of Respiratory Infections.

Authors:  Frantiescoli Dimer; Cristiane de Souza Carvalho-Wodarz; Jörg Haupenthal; Rolf Hartmann; Claus-Michael Lehr
Journal:  Pharm Res       Date:  2015-06-26       Impact factor: 4.200

5.  Rapid high performance liquid chromatographic method for determination of clarithromycin in human plasma using amperometric detection: application in pharmacokinetic and bioequivalence studies.

Authors:  Seyed Mohsen Foroutan; Afshin Zarghi; Alireza Shafaati; Babak Madadian; Farshid Abolfathi
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.